Search results for " trial"

showing 10 items of 3715 documents

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

2020

Abstract Background and aims Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD. Methods MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with c…

0301 basic medicineRelative risk reductionmedicine.medical_specialtyPopulationCoronary Artery Disease030204 cardiovascular system & hematologyCochrane Librarylaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawRisk FactorsInternal medicineAntithromboticmedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryAbsolute risk reductionAtherosclerosis030104 developmental biologyRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsAtherosclerosis
researchProduct

Strategies in DNA vaccine for melanoma cancer

2020

According to reports of the international agency for cancer on research, although malignant melanoma shows less prevalence than nonmelanoma skin cancers, it is the major cause of skin cancer mortality. Given that, the production of effective vaccines to control melanoma is eminently required. In this regard, DNA-based vaccines have been extensively investigated for melanoma therapy. DNA vaccines are capable of inducing both cellular and humoral branches of immune responses. These vaccines possess some valuable advantages such as lack of severe side effects and high stability compared to conventional vaccination methods. The ongoing studies are focused on novel strategies in the development …

0301 basic medicineSkin NeoplasmsDermatologyCancer VaccinesGeneral Biochemistry Genetics and Molecular BiologyDNA vaccination03 medical and health sciences0302 clinical medicineImmune systemVaccines DNAmedicineHumansMelanomaMelanoma-associated antigenbusiness.industryMelanomaCancermedicine.diseaseVaccinationClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologySkin cancerbusinessPigment Cell & Melanoma Research
researchProduct

The role of molecular enrichment on future therapies in hepatocellular carcinoma

2017

Summary Hepatocellular carcinomas (HCCs) are characterised by considerable phenotypic and molecular heterogeneity. Treating HCC and designing clinical trials are particularly challenging because co-existing liver disease, present in most patients, limits aggressive therapeutic options. Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities. However, failure of several large randomised controlled clinical trials over the last 10 years underlines the necessity for innovative treatment strategies and implementation of tran…

0301 basic medicineSorafenibOncologymedicine.medical_specialtyCarcinoma HepatocellularCabozantinibPhases of clinical research03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibmedicineHumansMolecular Targeted TherapyClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsPrecision medicinemedicine.diseasedigestive system diseasesClinical trial030104 developmental biologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaImmunotherapybusinessLenvatinibmedicine.drugJournal of Hepatology
researchProduct

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020

Proper trial design is critical for the success of clinical investigations. Hepatocellular carcinoma (HCC) is a complex disease that has several unique properties. In 2008, after the approval of sorafenib, a panel of experts proposed guidelines for trial design and endpoints in HCC that have been instrumental during the last decade and provided a framework to allow an homogeneous analysis of reported investigations. Since then, several phase III studies have been reported and novel challenges have emerged. A panel of experts conveyed by AASLD organized a Special Topic Conference on trial design and endpoints to address those emerging challenges. This review summarizes the analysis and concl…

0301 basic medicineSorafenibmedicine.medical_specialtyCarcinoma HepatocellularConsensusEndpoint DeterminationMEDLINEDisease03 medical and health sciences0302 clinical medicinemedicineHumansProgression-free survivalChemoembolization TherapeuticLiquid biopsyIntensive care medicineAdverse effectImmune Checkpoint InhibitorsProtein Kinase InhibitorsClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsLiquid Biopsymedicine.diseaseLiver TransplantationClinical trial030104 developmental biologyResearch DesignHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugHepatology
researchProduct

Is the pelvis-thorax coordination a valuable outcome instrument to assess patients with Hip osteoarthritis?

2020

Objective: The evaluation of the disease severity in hip osteoarthritis (OA) patients being currently based on subjective instruments. It would be of interest to develop more objective instruments, for example based on gait analysis. The aims of this study were to explore if pelvis-thorax coordination parameters could be valuable instrument outcomes to achieve this evaluation by assessing their reliability, discriminant capacity and responsiveness. Methods: Three groups of subjects; healthy, hip OA patients with severe disease (defined as indication to surgery), hip OA patients with less severe disease (no indication to surgery) were included. Hip OA patients with severe disease were evalua…

0301 basic medicineThoraxmedicine.medical_specialtyHistologyhiplcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyOsteoarthritisMARCHE A PIEDbiomechanicswalking03 medical and health sciencesBIOMECANIQUElcsh:TP248.13-248.65MedicineHANCHE[PHYS.MECA.BIOM]Physics [physics]/Mechanics [physics]/Biomechanics [physics.med-ph]PelvisOriginal ResearchCOORDINATIONddc:617business.industryBiomechanicsBioengineering and BiotechnologyMotor controlOUTCOME MEASURES021001 nanoscience & nanotechnologymedicine.diseaseClinical trial030104 developmental biologymedicine.anatomical_structureOSTEOARTHRITISCoronal planeGait analysisPhysical therapyoutcomes measuresCLINICAL GAIT ANALYSIS0210 nano-technologybusinessBiotechnology
researchProduct

Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subse…

2018

Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown. The objective of this study was to obtain evidence on whether TSAT determines the impact of experimental ischemic stroke on brain damage and whether iron-free transferrin (apotransferrin, ATf)-induced reduction of TSAT is neuroprotective. We found that experimental ischemic stroke promoted an early extravasation of circulating iron-loaded transferrin (holotransferrin, HTf) to the ischemic brain parenchyma.…

0301 basic medicineU-PAGE urea-polyacrylamide gel electrophoresisMaleClinical BiochemistryExperimental strokeBiochemistryBrain IschemiaBrain ischemia0302 clinical medicineADC apparent diffusion coefficientApotransferrinDWI diffusion-weighted imagingTANDEM-1 Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion clinical trialrHTf rat HTfrATf rat ATflcsh:QH301-705.5chemistry.chemical_classificationNeuronslcsh:R5-920ChemistryTransferrinExtravasationNS21 a medium supplement to grow neuronspDAPK-1 phosphorylated anti-death-associated protein kinase 1NeuroprotectionStrokeWB Western blotFemalemedicine.symptomlcsh:Medicine (General)Research PaperhHTf human HTfPC12 cell line derived from a pheochromocytoma of the rat adrenal medullamedicine.medical_specialtyIron OverloadBBB blood-brain barrierNMDAR N-methyl-D-aspartate receptorDCF dihydrofluoresceinIronWGA wheat germ agglutininHTf holotransferrinTransferrin receptorBrain damageTfR transferrin receptorDeferoxamineNeuroprotectionPI propidium iodide03 medical and health sciencesBrain damageCM conditioned mediumROS reactive oxygen speciesInternal medicine4-HNE 4-hydroxynonenalTf transferrinReceptors TransferrinmedicineFeRhoNoxTM-1 probe to detect Fe2+AnimalsHumansATf apotransferrinCM-H2DCFDA 5-chloromethyl-27-dichlorodihydrofluorescein diacetateMCAO middle cerebral artery occlusionDMT-1 divalent metal transporterB-27 a medium supplement to grow neuronsReactive oxygen speciesNMDA N-methyl-D-aspartateTSAT blood transferrin saturationTransferrin saturationBlood transferrin saturation (TSAT)Organic ChemistryNIR near infraredReactive oxygen species (ROS)medicine.diseasepMCAO permanent middle cerebral artery occlusionRatsPWI perfusion-weighted imaging030104 developmental biologyEndocrinologylcsh:Biology (General)TransferrinDAPK-1 anti-death-associated protein kinaseOGD oxygen/glucose deprivationTTC 235-triphenyl-tetrazolium chlorideLipid PeroxidationMCA middle cerebral arteryApoproteinsReactive Oxygen SpeciesMRI magnetic resonance imagingtMCAO transient middle cerebral artery occlusion030217 neurology & neurosurgeryhATf human ATf
researchProduct

Relationship between olive oil consumption and ankle-brachial pressure index in a population at high cardiovascular risk.

2020

[Background and aims]: The aim of this study was to ascertain the association between the consumption of different categories of edible olive oils (virgin olive oils and olive oil) and olive pomace oil and ankle-brachial pressure index (ABI) in participants in the PREDIMED-Plus study, a trial of lifestyle modification for weight and cardiovascular event reduction in individuals with overweight/obesity harboring the metabolic syndrome.

0301 basic medicineVirgin olive oils*Olive oil*Peripheral artery diseasePopulation*Olive pomace oil030204 cardiovascular system & hematologyOverweightToxicology03 medical and health sciences0302 clinical medicine*Virgin olive oils*Ankle-brachial pressure indexRisk Factorsmedicine*PREDIMED-Plus trialOlive pomace oilHumansPlant OilseducationOlive OilConsumption (economics)education.field_of_studyPeripheral artery diseaseMalalties cardiovascularsbusiness.industryPomacePREDIMED-Plus trialOdds ratiomedicine.diseaseObesityConfidence interval3. Good healthOli d'oliva030104 developmental biologyCross-Sectional StudiesCardiovascular DiseasesHeart Disease Risk FactorsAnkle-brachial pressure indexMetabolic syndromemedicine.symptomAnkleCardiology and Cardiovascular Medicinebusiness
researchProduct

Repurposing old drugs to fight multidrug resistant cancers.

2020

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approa…

0301 basic medicineVirtual screeningCancer ResearchDrug repurposingSettore BIO/11 - Biologia MolecolareAntineoplastic AgentsDrug resistanceBioinformatics03 medical and health sciencesClinical cancer trials; Drug repurposing; Multidrug resistant cancer; Pharmacophore modelling; Virtual screening0302 clinical medicineNeoplasmsDrug DiscoveryMedicineHumansPharmacology (medical)Computer SimulationRepurposingPharmacologyVirtual screeningDrug discoverybusiness.industryDrug RepositioningComputational BiologyDrug Resistance Multiple3. Good healthMultiple drug resistanceDrug repositioning030104 developmental biologyInfectious DiseasesOncologyDrug developmentDrug Resistance Neoplasm030220 oncology & carcinogenesisMultidrug resistant cancerPharmacophore modellingPharmacophorebusinessClinical cancer trialsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Mediterranean Diet Improves High-Density Lipoprotein Function in High-Cardiovascular-Risk Individuals: A Randomized Controlled Trial.

2017

Background: The biological functions of high-density lipoproteins (HDLs) contribute to explaining the cardioprotective role of the lipoprotein beyond quantitative HDL cholesterol levels. A few small-scale interventions with a single antioxidant have improved some HDL functions. However, to date, no long-term, large-scale, randomized controlled trial has been conducted to assess the effects of an antioxidant-rich dietary pattern (such as a traditional Mediterranean diet [TMD]) on HDL function in humans. Methods: This study was performed in a random subsample of volunteers from the PREDIMED Study (Prevención con Dieta Mediterránea; n=296) after a 1-year intervention. We compared the effects …

0301 basic medicineantioxidantAntioxidantlipid analysisMediterranean dietmedicine.medical_treatment030204 cardiovascular system & hematologyDiet MediterraneanDIETA MEDITERRÀNIAAntioxidantslaw.inventionlipoproteins HDLchemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinDietas.Randomized controlled triallawRisk FactorsCiències de la salutMiddle AgedCiencias de la saludLipidsRandomized controlled trialCardiovascular Diseaseslipids (amino acids peptides and proteins)AntioxidantCardiology and Cardiovascular MedicineLipoproteins HDLmedicine.medical_specialtyHDLrandomized controlled trial [publication type]Lipoproteinslipids03 medical and health sciencesPhysiology (medical)Internal medicinemedicineHumansDieta -- Mediterrània Regió de labusiness.industryCholesterolLÍPIDSHealth sciencesDiet030104 developmental biologyEndocrinologychemistry0009-7322dietbusinessFunction (biology)LipoproteinCirculation
researchProduct